In particular,Aldoxorubicin has to be mentioned, which was successfully tested ina clinical phase 3 trial against soft tissue sarcoma (NCT02049905).Aldoxorubicin is a doxorubicin-releasing prodrug, which binds selectivelyto albumin via a maleimide moiety upon i.v. application., During the last years, we have focused our research on the developmentof albumin-targeted platinum prodrugs. This evidence concerns the gene ALB and soft tissue sarcoma.